Lilly Doubles Weight-Loss Prescriptions After Novo’s Phase 2 Endpoint Miss
Eli Lilly commands twice the U.S. weekly weight-loss prescriptions of its nearest rival and holds a 25% valuation premium after Novo Nordisk’s obesity drug failed two primary endpoints in its Phase 2 trial. Novo’s setback drove a 4% share drop and reinforced Lilly’s market dominance.
1. Novo’s Phase 2 Endpoint Miss and Lilly’s Lead
Eli Lilly’s tirzepatide treatments now account for roughly two-thirds of U.S. weight-loss prescriptions, while Lilly maintains a 25% valuation premium over peers, following Novo Nordisk’s Phase 2 obesity drug that failed to achieve both primary weight-loss endpoints in its 12-week study. Novo’s shares fell 4% after the data release, underscoring rising investor confidence in Lilly’s market-leading position and fueling expectations for expanded insurance coverage and patient uptake for Lilly’s therapy.